- Home
- ORIQ vs ACET Comparison
ORIQ vs ACET Comparison
Compare ORIQ & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIQ | ACET |
|---|---|---|
| Founded | 2024 | 1947 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.6M | 93.5M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | ORIQ | ACET |
|---|---|---|
| Price | $10.16 | $0.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 5.1K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.45 |
| 52 Week High | $10.20 | $1.12 |
Technical Indicators
Market Signals| Indicator | ORIQ | ACET |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.12 |
| Support Level | N/A | $0.50 |
| Resistance Level | N/A | $0.57 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 18.38 |
Price Performance
Historical ComparisonAbout ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.